A number of stocks jumped in the afternoon session after comments from a key Federal Reserve official bolstered hopes for an interest rate cut. New York Federal Reserve President John Williams stated he sees “room for a further adjustment” in the near term, sparking a significant market rally. Following his remarks, the probability of the central bank cutting rates at its December meeting jumped from 39% to over 73%, according to the CME FedWatch tool. This positive sentiment provided relief to markets amid concerns over high valuations, particularly in AI-related stocks.
Wall Street has issued downbeat forecasts for the stocks in this article.
These predictions are rare - financial institutions typically hesitate to say bad things about a company because it can jeopardize their other revenue-generating business lines like M&A advisory.
We're back with the second episode of a new series -- 10 Years Later -- where we blast through time to check in on a five-stock sampler from 10 years in the past.
Globus Medical’s third quarter results were met with a significant positive market reaction, reflecting the company’s outperformance on key metrics. Management attributed the strong quarter to robust growth in its U.S. Spine business and sustained contribution from the recently integrated Nevro business. CEO Keith Pfeil emphasized the breadth of growth across the core implant portfolio and highlighted the impact of aggressive competitive recruiting. He stated, “All signs point to strength within this core objective,” noting 32 consecutive weeks of growth in U.S. Spine. Operational efficiencies and synergy realization from the Nevro acquisition further supported margin expansion and profitability.
Exciting developments are taking place for the stocks in this article.
They’ve all surged ahead of the broader market over the last month as catalysts such as new products and positive media coverage have propelled their returns.
Curious to know what's happening on the US markets one hour before the close of the markets on Friday? Join us as we explore the top gainers and losers in today's session.
Shares of medical device company Globus Medical (NYSE:GMED)
jumped 32.7% in the afternoon session after the company reported third-quarter results that significantly beat analyst estimates and raised its full-year guidance.
Medical device company Globus Medical (NYSE:GMED) beat Wall Street’s revenue expectations in Q3 CY2025, with sales up 22.9% year on year to $769 million. The company’s full-year revenue guidance of $2.88 billion at the midpoint came in 0.8% above analysts’ estimates. Its non-GAAP profit of $1.18 per share was 53.4% above analysts’ consensus estimates.
As the US market prepares to open on Friday, let's get an early glimpse into the pre-market session and identify the stocks leading the pack in terms of gains and losses.
Globus Medical's Q3 2025 earnings crushed estimates, with EPS of $1.18 beating by 47%. The stock surged over 22% as the company also raised its full-year profit guidance.
Medical device company Globus Medical (NYSE:GMED) announced better-than-expected revenue in Q3 CY2025, with sales up 22.9% year on year to $769 million. The company’s full-year revenue guidance of $2.88 billion at the midpoint came in 0.8% above analysts’ estimates. Its non-GAAP profit of $1.18 per share was 53.4% above analysts’ consensus estimates.
